Clinical Efficacy and Adverse Reaction of Torasemide Combined with Bisoprolol in the Treatment of Patients with Essential Hypertension Complicated with Systolic Heart Failure

Abstract

Abstract: Objective To study the clinical efficacy of torasemide combined with bisoprolol in the treatment of patients with essential hypertension complicated with systolic heart failure. Methods 134 patients with essential hypertension and systolic heart failure admitted to our hospital from May 2016 to June 2018 were enrolled in the study. According to the random number table method, control group (torasemide treatment) 67 cases and study group (torasemide combined with bisoprolol treatment) 67 cases. Blood pressure, cardiac function, biochemical parameters, clinical efficacy and adverse reactions were compared before and after treatment. Results The total effective rate of treatment in the study group (95.52%) was significantly higher than the control group (80.60%), and the difference was statistically significant (P <0.05). Before and after treatment, the systolic blood pressure, diastolic blood pressure and 24 h blood pressure variability were significantly different (P<0.05). After treatment, the systolic blood pressure, diastolic blood pressure and 24 h blood pressure variability of the study group were significantly lower than the control group, the difference was statistically significant (P<0.05). Before and after treatment, the left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD) and heart rate were significantly lower than those before treatment, and left ventricular ejection fraction (LVEF) was significantly increased. The difference was statistically significant (P<0.05). Compared with the control group, the LVEDD, LVESD and heart rate in the study group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). Compared with before and after treatment, superoxide dismutase (SOD) was significantly increased, malondialdehyde (MDA) and brain natriuretic peptide (BNP) were significantly decreased (P<0.05). After treatment, the SOD of the study group was significantly higher than the control group, and the MDA and BNP were significantly lower than the control group (P<0.05). The incidence of adverse reactions (8.96% vs 11.94%) was not significantly different (P>0.05). Conclusion Torasemide combined with bisoprolol is effective in the treatment of essential hypertension complicated with heart failure. It is also helpful to improve cardiac function, stabilize blood pressure, inhibit oxidative stress, and have low incidence of adverse reactions and higher safety.

Key words: torasemide, bisoprolol, essential hypertension, heart failure

CLC Number:

R994.11

ZHANG Shengzhang, HUANG Weijian. Clinical Efficacy and Adverse Reaction of Torasemide Combined with Bisoprolol in the Treatment of Patients with Essential Hypertension Complicated with Systolic Heart Failure[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 467-472.

References

[1] Walker A M, Patel P A, Rajwani A, et al.Diabetes mellitus is associated with adverse structural and functional cardiac remodelling in chronic heart failure with reduced ejection fraction[J]. Diab Vasc Dis Res, 2016, 13(5): 331-340.
[2] 靳新民. 二甲双胍对高血压合并2型糖尿病患者心室重塑的影响[J]. 中国药物警戒, 2016, 13(1):9-12.
[3] 黄莹, 姚汉玲, 黄 . 托拉塞米治疗AECOPD患者心力衰竭的临床疗效及安全性分析[J].中国医院药学杂志, 2018, 38(18):1964-1966.
[4] 王和银, 谭咏梅, 张兴展, 等.比索洛尔与美托洛尔对原发性高血压患者心率、心率变异性和临床事件的影响[J]. 中华高血压杂志, 2014, 22(2):184-186.
[5] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南[J]. 中华心血管病杂志, 2014, 42(2): 98-122.
[6] 周海蓉, 段学燕, 赵力敏, 等. 托拉塞米联合环磷腺苷葡胺治疗老年慢性心功能不全的应用价值[J]. 中国老年学杂志, 2018, 38(18):4374-4376.
[7] Makoto S, Kazuaki N, Thomas H M.Meta-Analysis of Risks for Short-Term Readmission in Patients With Heart Failure[J]. Am J Cardiol, 2016,117(4): 626-632.
[8] Bart omiej P, Martyna O, Agnieszka S, et al. Central Chemoreceptor Sensitivity Is Not Enhanced in Contemp- orary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment[J]. J Card Fail, 2017, 23(1): 83-87.
[9] Allida S M, Inglis S C, Davidson P M, et al.Thirst in chronic heart failure: a review[J]. J Clin Nurs, 2015, 24(7/8): 916-926.
[10] 陈端, 侯伟宁, 钟世勤, 等.替米沙坦对使用美托洛尔治疗的慢性心力衰竭合并高血压、糖耐量受损患者糖代谢的影响研究[J]. 实用心脑肺血管病杂志, 2014, 22(8):14-16.
[11] 吴锦波, 叶小汉, 冼绍祥, 等.比索洛尔对心力衰竭大鼠心肌肌浆网钙三磷酸腺苷酶2a活性的影响[J].中华高血压杂志, 2017, 25(6):560-564.
[12] Kassandra S T, Guy L O, Charles E M, et al.Translation of Cardiac Myosin Activation With 2-Deoxy-ATP to Treat Heart Failure Via an Experimental Ribonucleotide Reductase-Based Gene Therapy[J]. JACC: Basic to Transl -ational Science, 2016, 1(7): 666-679.
[13] 吴锦波, 叶小汉, 冼绍祥, 等. 比索洛尔对心力衰竭大鼠心肌肌浆网钙ATP酶2a活性的影响[J]. 临床心血管病杂志, 2017, 33(1):86-91.
[14] Skrabal F, Pichler G P, Gratze G, et al.Adding "hemodynamic and fluid leads" to the ECG. Part I:the electrical estimation of BNP,chronic heart failure (CHF) and extracellular fluid (ECF) accumulation[J]. Med Engineer Phys, 2014, 36(7):896-904.
[15] Nokamura K, Miura D, Matsubara H, et al.Oxidative stress and calcium overload in heart failure[J]. Folia Pharmacologica Japonica, 2012, 140(6):265-269.
[16] 郭丽, 张丽, 邓萌. 比索洛尔对心力衰竭大鼠氧化应激及细胞凋亡的影响[J]. 中国老年学杂志, 2017, 37(20): 4999-5000.